|
1
|
Dinkelspiel HE, Champer M, Hou J, Tergas
A, Burke WM, Huang Y, Neught AI, Ananth CV, Hershman DL and Wright
JD: Long-term mortality among women with epithelial ovarian cancer.
Gynecol Oncol. 138:421–428. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liberto JM, Chen SY, Shih IM, Wang TH,
Wang TL and Pisanic TR II: Current and emerging methods for ovarian
cancer screening and diagnostics: A comprehensive review. Cancers
(Basel). 14:28852022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Smith LH, Morris CR, Yasmeen S,
Parikh-Patel A, Cress RD and Romano PS: Ovarian cancer: Can we make
the clinical diagnosis earlier? Cancer. 104:1398–1407. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Takada H, Wakabayashi N, Dohi O, Yasui K,
Sakakura C, Mitsufuji S, Taniwaki M and Yoshizawa T: Tissue factor
pathway inhibitor 2 (TFPI2) is frequently silenced by aberrant
promoter hypermethylation in gastric cancer. Cancer Genet
Cytogenet. 197:16–24. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hibi K, Goto T, Kitamura YH, Yokomizo K,
Sakuraba K, Shirahata A, Mizukami H, Saito M, Ishibashi K, Kigawa
G, et al: Methylation of TFPI2 gene is frequently detected in
advanced well-differentiated colorectal cancer. Anticancer Res.
30:1205–1207. 2010.PubMed/NCBI
|
|
8
|
Sun FK, Fan YC, Zhao J, Zhang F, Gao S,
Zhao ZH, Sun Q and Wang K: Detection of TFPI2 methylation in the
serum of hepatocellular carcinoma patients. Dig Dis Sci.
58:1010–1015. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Arakawa N, Miyagi E, Nomura A, Morita E,
Ino Y, Ohtake N, Miyagi Y, Hirahara F and Hirano H: Secretome-based
identification of TFPI2, a novel serum biomarker for detection of
ovarian clear cell adenocarcinoma. J Proteome Res. 12:4340–4050.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Miyagi E, Arakawa N, Sakamaki K, Yokota
NR, Yamanaka T, Yamada Y, Yamaguchi S, Nagao S, Hirashima Y,
Kasamatsu Y, et al: Validation of tissue factor pathway inhibitor 2
as a specific biomarker for preoperative prediction of clear cell
carcinoma of the ovary. Int J Clin Oncol. 26:1336–1344. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Arakawa N, Kobayashi H, Yonemoto N,
Masuishi Y, Ino Y, Shigetomi H, Furukawa N, Ohtake N, Miyagi Y,
Hirahara F, et al: Clinical significance of tissue factor pathway
inhibitor 2, a serum biomarker candidate for ovarian clear cell
carcinoma. PLoS One. 11:e01656092016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kobayashi H, Yamada Y, Kawaguchi R, Ootake
N, Myoba S and Kimura F: Tissue factor pathway inhibitor 2: A
potential diagnostic marker for discriminating benign from
malignant ovarian tumors. J Obstet Gynaecol Res. 48:2442–2451.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Miyake R, Yamada Y, Yamanaka S, Kawaguchi
R, Ootake N, Myoba S and Kobayashi H: Tissue factor pathway
inhibitor 2 as a serum marker for diagnosing asymptomatic venous
thromboembolism in patients with epithelial ovarian cancer and
positive D-dimer results. Mol Clin Oncol. 16:1–5. 2022.PubMed/NCBI
|
|
14
|
Yamanaka S, Miyake R, Yamada Y, Kawaguchi
R, Ootake N, Myoba S and Kobayashi H: Tissue factor pathway
inhibitor 2: A novel biomarker for predicting asymptomatic venous
thromboembolism in patients with epithelial ovarian cancer. Gynecol
Obstet Invest. 87:133–140. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kawaguchi R, Maehana T, Yamanaka S, Miyake
R, Kawahara N, Iwai K, Yamada Y and Kimura F: Preoperative serum
tissue factor pathway inhibitor-2 level as a prognostic marker for
endometrial cancer: A single-center retrospective study. Oncol
Lett. 26:4632023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Prat J; FIGO Committee on Gynecologic
Oncology, : Staging classification for cancer of the ovary,
fallopian tube, and peritoneum. Int J Gynaecol Obstet. 124:1–5.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kurman RJ and Shin IM: Molecular
pathogenesis and extraovarian origin of epithelial ovarian cancer.
Shifting the paradigm. Hum Pathol. 42:918–931. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nagell JRV, Burgess BT, Miller RW, Baldwin
L, DeSimone CP, Ueland FR, Huang B, Chen Q, Kryscio RJ and Pavlik
EJ: Survival of women with type I and II epithelial ovarian cancer
detected by ultrasound screening. Obstet Gynecol. 132:1091–1100.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kawahara N, Kawaguchi R, Maehana T,
Yamanaka S, Yamada Y, Kobayashi H and Kimura F: The endometriotic
neoplasm algorithm for risk assessment (e-NARA) index sheds light
on the discrimination of endometriosis-associated ovarian cancer
from ovarian endometrioma. Biomedicines. 10:26832022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nakamura M, Obata T, Daikoku T and
Fujiwara H: The association and significance of p53 in gynecologic
cancers: The potential of targeted therapy. Int J Mol Sci.
20:54822019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Throwba HPK, Unnikrishnan L, Pangath M,
Vasudevan K, Jayaraman S, Li M, Iyaswamy A, Palaniyandi K and
Gnanasampanthapandian G: The epigenetic correlation among ovarian
cancer, endometriosis and PCOS: A review. Crit Rev Oncol Hematol.
180:1038522022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kurman RJ and Shih IM: The dualistic model
of ovarian cancer. Am J Pathol. 186:733–747. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Charkhchi P, Cybulski C, Gronwald J, Wong
FO, Narod SA and Akbari MR: CA125 and ovarian cancer: A
comprehensive review. Cancers (Basel). 12:37302020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tang H, Liu Y, Wang X, Guan L, Chen W,
Jiang H and Lu Y: Clear cell carcinoma of the ovary
Clinicopathologic features and outcomes in a Chinese cohort.
Medicine (Baltimor). 97:e108812018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu C, Zhu J, Qian L, Liu H, Shen Z, Wu D,
Zhao W, Xiao W and Zhou Y: Clinical characteristics and prognosis
of ovarian clear cell carcinoma: A 10-year retrospective study. BMC
Cancer. 21:3222021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ota Y, Koizumi S, Nakamura Y, Yoshihara M,
Takahashi T, Sato S, Myoba S, Ohtake N, Kato H, Yokose T, et al:
Tissue factor pathway inhibitor-2 is specifically expressed in
ovarian clear cell carcinoma tissues in the nucleus, cytoplasm and
extracellular matrix. Oncol Rep. 45:1023–1032. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Matsuzaki S, Yoshino K, Ueda Y, Matsuzaki
S, Kakuda M, Okazawa A, Egawa-Takata T, Kobayashi E and Kimura T:
Potential targets for ovarian clear cell carcinoma: A review of
updates and future perspectives. Cancer Cell Int. 15:1172015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wojtukiewicz MZ, Sierko E, Zimnoch L,
Kozlowski L and Kisiel W: Immunohistochemical localization of
tissue factor pathway inhibitor-2 in human tumor tissue. Thromb
Haemost. 90:140–146. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kawaguchi R, Maehana T, Sugimoto S,
Kawahara N, Iwai K, Yamada Y and Kimura F: Immunohistochemical
analysis of the tissue factor pathway inhibitor-2 in endometrial
clear cell carcinoma: A single-center retrospective study. Int J
Gynecol Pathol. 43:25–32. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jacobs I and Oram D: Screening for ovarian
cancer. Biomed Pharmacother. 42:589–596. 1988.PubMed/NCBI
|
|
31
|
Chen SY, Chang TC, Lin CY, Lai CH, Wu RC,
Yang LY, Chang WY, Lee YS, Yang WV and Chao A: Serum levels of
alpha1-antitrypsin isoforms in patients with ovarian clear cell
carcinoma: An exploratory study. J Chin Med Assoc. 84:1048–1053.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Muyldermans M, Cornillie FJ and Koninckx
PR: CA125 and endometriosis. Hum Reprod Update. 1:173–187. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Morales-Vásquez F, Pedernera E,
Reynaga-Obregón J, López-Basave HN, Gómora MJ, Carlón E, Cárdenas
S, Silva-Ayala R, Almaraz M and Méndez C: High levels of
pretreatment CA125 are associated to improved survival in high
grade serous ovarian carcinoma. J Ovarian Res. 9:412016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Colaković S, Lukiç V, Mitroviç L, Jeliç S,
Susnjar S and Marinkoviç J: Prognostic value of CA125 kinetics and
half-life in advanced ovarian cancer. Int J Biol Markers.
15:147–152. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kawahara N, Kawaguchi R, Waki K, Maehana
T, Yamanaka S, Yamada Y and Kimura F: The prognosis predictive
score around primary debulking surgery (PPSP) improves diagnostic
efficacy in predicting the prognosis of ovarian cancer. Sci Rep.
12:226362022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gadducci A, Multinu F, Cosio S, Carinelli
S, Ghioni M and Aletti GD: Clear cell carcinoma of the ovary:
Epidemiology, pathological and biological features, treatment
options and clinical outcomes. Gynecol Oncol. 162:741–750. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lin JX, Huang YQ, Wang ZK, Xie JW, Wang
JB, Lu J, Chen QY, Cao LL, Lin M, Tu RH, et al: Prognostic
importance of dynamic changes in systemic inflammatory markers for
patients with gastric cancer. J Surg Oncol. 124:282–292. 2021.
View Article : Google Scholar : PubMed/NCBI
|
